Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients

Nosocomial infections caused by drug-resistant Acinetobacter baumannii are a major global problem [1]. Recent data from the Chinese Network for Bacterial-resistance Surveillance demonstrated that the susceptibility of A. baumannii to carbapenems has decreased to below 50%, and almost 17% of these isolates are resistant to all antimicrobial agents that are routinely used in clinical practice [2]. Unfortunately, no new antibiotics will be available for extensive drug resistant (XDR) gram-negative pathogens including A. baumannii for at least a decade [3]. These data highlight the importance and urgency of finding antibiotic combinations that are effective in the treatment of infections caused by this problematic "superbug".

"Old" antibiotics, such as colistin [4] and minocycline [5], are generally active against A. baumannii strains. Colistin was withdrawn from general clinical use in the late 1970s because of potential nephrotoxicity and neurotoxicity, but now it is increasingly used worldwide as the last-line therapy against A. baumannii [6‐8]. Colistin activity can be enhanced when combined with some other antibiotics with different modes of action such as carbapenems, rifampicin and ceftazidime [9‐13]. Minocycline is a second-line antibiotic for a number of common bacterial infections in the clinical setting. Recent studies have indicated that minocycline is a promising drug for the treatment of A. baumannii infections [5, 14]. Furthermore, it can enhance the activity of colistin against multidrug-resistant A. baumannii isolates [15].

In order to find the combinations that would achieve complete killing or are bactericidal against XDR-AB isolates, we examined the activities of colistin- and minocycline-based combinations, including colistin/meropenem, colistin/rifampicin, colistin/minocycline and minocycline/meropenem, against XDR-AB isolates from patients in the intensive care unit (ICU) of Huashan Hospital, a 1,400-bed hospital in eastern China.

The PCR fingerprints demonstrated that the strains belonged to four clonotypes termed clonotype I, II, III and IV (Table 1). The MICs of colistin, minocycline, meropenem and rifampicin are summarized in Table 1. All isolates were resistant to meropenem but susceptible to colistin and minocycline. The MICs of rifampicin ranged from 4 to 16 μg/mL.

In the time-kill study, no viable cells were detected at 2 to 4 hours in the presence of 1×MIC colistin, and regrowth was not observed at 24 hours (data not shown). When the concentration of colistin was 0.5×MIC, the growth of isolates 09-1769 and 10-548 was markedly reduced (Figure 1B and 1D), but the growth of isolates 09-95 and 09-2092 was only slightly inhibited compared with the controls (Figure 1A and 1C). An important phenomenon was observed in that complete killing of all strains was achieved within 2-6 hours when high concentrations of meropenem (16 μg/mL), minocycline (2 μg/mL) or rifampicin (0.25 μg/mL) were applied in combination with 0.5×MIC colistin. When combined with colistin, the lowest concentrations of minocycline, meropenem and rifampicin presenting a synergistic effect were identified for different strains (Figure 1A, B, C and 1D). For meropenem, 4 μg/mL (i.e., 1/8-1/32 MIC) was sufficient to present a synergistic effect with colistin against three strains (not isolate 09-1769) which represent 92% of the total strains. Similarly, a minocycline concentration as low as 1 μg/mL (i.e., 1/4-1/8 MIC) also showed synergy with colistin against all four isolates. The lowest concentration of rifampicin of 0.06 μg/mL also exhibited a synergistic effect with colistin (no combination of rifampicin at a concentration of less than 0.06 μg/mL with colistin was included in present work).

In the time-kill study with minocycline and meropenem alone, the growth of all isolates was inhibited by 0.5×MIC minocycline, but not affected by 16 μg/mL meropenem alone (Figure 2). Interestingly, synergistic activity was observed when meropenem was combined with minocycline. A combination of 16 μg/mL meropenem with 0.5×MIC minocycline exhibited bactericidal activities against all strains at 12 h (Figure 2). Isolate 09-95 showed susceptibility to this combination with 8 μg/mL meropenem (data not shown).

The mean survival times of each XDR-AB strain under different drug treatments are shown in Figure 3. The data indicated that MST_{12 h} values of colistin- or minocycline-based combinations were significantly shorter than that of each drug alone. On average, the MST_{12 h} values of colistin-based drug combinations were 3.1 hours shorter than any constituent drug alone (Figure 3A) (p < 0.01). The MST_{12 h} value of the minocycline/meropenem combination was 1.6 hours shorter than that of minocycline or meropenem alone (Figure 3B) (p < 0.01).

Colistin is unavailable in China, so data are limited here regarding colistin in the treatment of infections caused by multidrug-resistant gram-negative bacteria. The 14 XDR-AB strains used in this study were isolated from patients in the ICU in Huashan Hospital, where there is a high incidence of severe infections and a major presence of XDR-AB. We demonstrated that colistin was active against all the strains at a lower MIC (MIC₉₀ = 0.5 μg/mL) than in other reports [21]. This may arise from the fact that colistin has not yet been approved for clinical use in China. The results of the study were in accordance with previous reports that colistin/meropenem [9], colistin/rifampicin [10] and colistin/minocycline [15] combinations were synergistic against these strains.

It was considered that colistin should be combined with other drugs for lower dose-related toxicity, and recent research has suggested that it is necessary to combine colistin with another antibiotic to obtain a pharmacological effect. The most frequently used form of colistin is colistin methanesulfonate (CMS), which is a prodrug of colistin without activity [22]. In vivo, CMS is hydrolyzed to produce the active colistin. Pharmacokinetic studies have indicated that the recommended intravenous dose of CMS will present a stable level of colistin in plasma of 1-4 μg/mL [23], which should have activity against most A. baumannii strains (the MIC is 0.5-1 μg/mL). However, if protein-binding is considered [24], the concentration of free drug is likely to be reduced to 0.3-1.2 μg/mL, i.e., the concentration of colistin is under the MIC in many cases, which may result in treatment failure and increase the risk of drug resistance. To, combine it with meropenem (≥ 8 μg/mL), minocycline (≥ 1 μg/mL) or rifampicin (≥ 0.06 μg/mL) may achieve bactericidal effects according to our results. Further observations are warranted in light of these data.

As in some recent reports [5, 14, 15], our study also demonstrated that minocycline is generally active against A. baumannii. Here, the MIC of minocycline for the 14 strains was 4 μg/mL. Because of dose-dependent gastrointestinal and vestibular function disorders [25] and the risk of drug resistance, minocycline alone is generally considered unfavorable for the treatment of XDR-AB, but it may have promising effects in combination with other antibiotics. In addition to the colistin/minocycline combination, our results also showed that minocycline combined with meropenem was effective against XDR-AB isolates. Our findings point to a possible option for treatment of XDR-AB infections when colistin or CMS is unavailable.